WO2004039148A1 - 非細菌性前立腺炎モデル動物 - Google Patents
非細菌性前立腺炎モデル動物 Download PDFInfo
- Publication number
- WO2004039148A1 WO2004039148A1 PCT/JP2003/013743 JP0313743W WO2004039148A1 WO 2004039148 A1 WO2004039148 A1 WO 2004039148A1 JP 0313743 W JP0313743 W JP 0313743W WO 2004039148 A1 WO2004039148 A1 WO 2004039148A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacterial prostatitis
- human
- prostatitis
- animal
- hydrochloric acid
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 192
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 101
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 238
- 230000001684 chronic effect Effects 0.000 claims abstract description 91
- 206010069918 Bacterial prostatitis Diseases 0.000 claims description 197
- 210000002307 prostate Anatomy 0.000 claims description 153
- 238000012360 testing method Methods 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 82
- 239000000126 substance Substances 0.000 claims description 67
- 239000003814 drug Substances 0.000 claims description 65
- 208000014001 urinary system disease Diseases 0.000 claims description 61
- 208000026723 Urinary tract disease Diseases 0.000 claims description 60
- 229940079593 drug Drugs 0.000 claims description 59
- 210000001519 tissue Anatomy 0.000 claims description 59
- 239000002775 capsule Substances 0.000 claims description 45
- 208000024891 symptom Diseases 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 40
- 230000002485 urinary effect Effects 0.000 claims description 33
- 208000035475 disorder Diseases 0.000 claims description 32
- 231100000827 tissue damage Toxicity 0.000 claims description 32
- 230000000451 tissue damage Effects 0.000 claims description 30
- 238000012216 screening Methods 0.000 claims description 25
- 238000009395 breeding Methods 0.000 claims description 22
- 230000001488 breeding effect Effects 0.000 claims description 22
- 230000003405 preventing effect Effects 0.000 claims description 22
- 230000037396 body weight Effects 0.000 claims description 21
- 230000006872 improvement Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 206010036018 Pollakiuria Diseases 0.000 claims description 16
- 238000011156 evaluation Methods 0.000 claims description 16
- 208000026062 Tissue disease Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 238000003860 storage Methods 0.000 claims description 13
- 206010046543 Urinary incontinence Diseases 0.000 claims description 12
- 210000002700 urine Anatomy 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 238000010171 animal model Methods 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 229940043274 prophylactic drug Drugs 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 abstract description 15
- 230000001575 pathological effect Effects 0.000 abstract description 13
- 206010061397 Urinary tract injury Diseases 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 description 102
- 241000700159 Rattus Species 0.000 description 99
- 230000027939 micturition Effects 0.000 description 57
- 239000007924 injection Substances 0.000 description 41
- 238000002347 injection Methods 0.000 description 41
- 230000006870 function Effects 0.000 description 21
- 206010046555 Urinary retention Diseases 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 210000003708 urethra Anatomy 0.000 description 16
- 208000013507 chronic prostatitis Diseases 0.000 description 15
- 210000001177 vas deferen Anatomy 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 230000007170 pathology Effects 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000004064 dysfunction Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 206010013990 dysuria Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 230000000762 glandular Effects 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 150000002484 inorganic compounds Chemical class 0.000 description 6
- 229910010272 inorganic material Inorganic materials 0.000 description 6
- 150000002894 organic compounds Chemical class 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 210000001635 urinary tract Anatomy 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 208000017497 prostate disease Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 201000002327 urinary tract obstruction Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000036318 urination frequency Effects 0.000 description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010061876 Obstruction Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940124350 antibacterial drug Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000005068 bladder tissue Anatomy 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 208000022934 urinary frequency Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001700 effect on tissue Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000009506 keishibukuryogan Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- RBPVKPJDVPPRMI-AVXONLMPSA-N 2-aminoacetic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid Chemical compound NCC(O)=O.C[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O RBPVKPJDVPPRMI-AVXONLMPSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241001416090 Ardea cinerea Species 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010049576 Bladder neck sclerosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000019229 Dinia Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010061979 Genital pain Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- HSVIINWFPKEOEQ-NSHDSACASA-N Ofloxacin methyl ester Chemical compound C([C@H](C)N1C=C(C(C(=C11)C=C2F)=O)C(=O)OC)OC1=C2N1CCN(C)CC1 HSVIINWFPKEOEQ-NSHDSACASA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 206010061339 Perineal pain Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036968 Prostatic pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000008695 cernilton Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000036724 intravesical pressure Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000024722 urethra neoplasm Diseases 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
Definitions
- the present invention relates to a chronic non-bacterial prostatitis model animal and a method for producing the same. More specifically, the present invention relates to a non-human animal that mimics human chronic non-bacterial prostatitis and a method for producing the same. Furthermore, the present invention provides a method for selecting a substance effective for prevention or treatment of human chronic non-bacterial prostatitis using the model animal, and a method for selecting a human chronic non-bacterial non-bacterial prostatitis using the substance selected by the method as an active ingredient.
- the present invention relates to a pharmaceutical composition for preventing or treating bacterial prostatitis.
- the present invention also relates to a method for evaluating the efficacy of a pharmaceutical composition for preventing or treating human chronic nonbacterial prostatitis using the above model animal. Background art
- Prostatitis is a relatively common urological disorder that affects adult men.
- prostatitis accounts for the highest proportion of urological disorders (0.77% of total outpatients (approximately 5% of outpatients with urological disorders) )].
- the third most common disease (0.83% of the total number of outpatients) is reported in men over the age of 50 after prostatic hypertrophy and prostate cancer (Collins, MM .: How common is prostatitis? A national survey of physician visits. J Urol 159: 1224-1228, 1998).
- about 2 million people are diagnosed with prostatitis each year.
- the frequency of bacterial prostatitis in (1) and (2) was slight, and non-bacterial prostatitis in (3) and (4) There is a report that it accounts for a large number (Souichi Arakawa: Causes and Treatment of Prostatitis Syndrome. Nippon Medical Shinpo, 017: 25-30, Ran).
- the clinical condition can be broadly divided into (1) acute diseases and (2), (3) and (4) chronic diseases.
- acute bacterial prostatitis which is classified as acute (1), in addition to fever as a symptom, so-called bladder symptoms caused by inflammation spreading from the bladder horn to the posterior urethra include urinary pain, frequent urination, A feeling of residual urine is observed.
- Chronic prostatitis (2), (3) and (4) which are classified as chronic, include bladder symptoms such as frequent urination and urination, and uncertain complaints in the perineum and lower abdomen.
- pollakiuria is one of the typical symptoms that are recognized relatively frequently (Souichi Arakawa: Prostatitis and frequent urination. This month's treatment 6: 863-865, 1998).
- Chronic prostatitis is classified into three types ((2), (3), (4)) as described above, but the clinical conditions are very similar to each other. It is difficult to change the pattern (Masayoshi Yokoyama: [All about prostate care] Prostatitis and prostatodinia. Clinical Science 33: 1561-1567, 1997).
- Acute bacterial prostatitis (ABP) is contraindicated because there is a risk of causing sepsis by performing a four-glass test, but chronic prostatitis ((2), (3), (4) )) Is a four-glass test to check for bacteria in EPS (expressed prostatic secretion ⁇ prostate extract collected during gland massaging) and VB3 (Voided bladder 3, initial urine after mass prostate massing) This makes it possible to distinguish between bacterial and non-bacterial.
- EPS expressed prostatic secretion ⁇ prostate extract collected during gland massaging
- VB3 Vehicle 3, initial urine after mass prostate massing
- non-bacterial prostatitis can be distinguished from prostate pain by the presence or absence of leukocytes in EPS (Masashi Yokoyama: [All Prostate Practices] Prostatitis and Prostat Dinia. Clinical Science 33: 1561—1567, 1997) .
- NIH-CPSI National Institutes of Health chronic prostatitis symptom index
- This NIH-CPSI uses the symptoms of chronic prostatitis, which is characterized by various clinical symptoms, as a symptom score.
- the etiology of chronic nonbacterial prostatitis can be as diverse as prostatic fluid stasis, involvement of autoimmunity and allergies, involvement of microorganisms such as Mycoplasma and Chlamydia trachomatis, sex hormone imbalance, and psychological factors [Pewit t, EB., Schaeffer, AJ .: Urinary tract infection in urology: including acute and chronic prostatitis. Infect Dis Clin North Am. 11: 623-646, 1997; Donovan, DA., Nicholas, PK .: Diagnosis and treatment in primary care. Nurse Practitioner. 22: 144-156, 1997].
- bladder and urethra are collectively called It is thought that there is a spillover effect on the lower urinary tract) or an effect on the nervous system related to urination, which may cause pain and urination stimulating symptoms [Tazuji Tsukamoto, Masashi Masuka Mori Naoya: Symptoms of urination and the prostate. Jichi Medical Journal. 119: 609-612, 1998].
- diseases that cause lower urinary tract disorders include cystitis, urethritis, prostatitis, frequent urinary frequency, bladder neurosis, Interstitial cystitis, etc.), as well as urinary obstruction symptoms (dysuria) such as difficulty urinating and urinary retention, bladder detrusor contraction disorder, bladder neck sclerosis, bladder tumor, prostate cancer, Prostatitis, urethral stricture, and urethral tumors have been reported [Ryuichiro Miyatake, Takashi Kurita: Differential diagnosis from dysuria due to benign prostatic hypertrophy and other causes.
- prostatitis is a disease in which both urinary stimulatory symptoms (urinary dysfunction) and urinary obstruction symptoms (urinary dysfunction) of lower urinary tract disorders can occur simultaneously. Therefore, development of new treatment methods and therapeutic agents for prostatitis including improvement of such lower urinary tract disorders is desired.
- various attempts have been made in basic research to produce various prostatitis model animals. For animal models of bacterial prostatitis, model animals can be produced by direct inoculation of causative bacteria.
- model animals of non-bacterial prostatitis mainly, there are methods for preparing model animals by autoimmune reaction, and preparing model animals by imbalanced hormonal balance by overdose of androgen and estrogen. it can.
- Other methods include the preparation of model animals by partial obstruction of the urethra using surgical techniques, the generation of spontaneous model animals by aging, the generation of model animals by stress stimulation, and the preparation of model animals by direct prostate inoculation of lipopolysaccharide (LPS).
- LPS lipopolysaccharide
- model animals Preparation of model animals by injecting drugs into female rats during pregnancy and lactation and inducing spontaneous onset of prostatitis in male birth rats; generation of model animals by continuous ingestion of diets with altered ingredients; Production of model animals by inoculation of inflammatory microorganisms (Chlamydia) can be mentioned.
- Studies on these model animals have shown that inflamed prostate His research focuses on histopathological examination of tissues, accompanying changes in inflammatory site forces, parameters related to inflammatory cell infiltration (mast cells and lymphocytes), and changes in inflammation-related genes. Therefore, there is no research report focusing on subjective symptoms (urinary dysfunction, pain, Q0L) which are problematic in clinical practice.
- a prostatitis model animal that reflects the clinical pathology that has both lower prostatic tissue disorders and lower urinary tract disorders can be created, the effect of improving prostate tissue disorders and lower urinary tract It is possible to evaluate both the ameliorating effects on disorders in the same model at the same time, and to develop a model animal (screening model) used for screening active ingredients and pharmacodynamics in developing prostatitis prophylactic / therapeutic agents. Animal) is expected to be very useful.
- Non-bacterial prostatitis presents with urinary frequency (urinary storage disorder) due to edema and swelling due to inflammation, and prostate-related pain syndrome involves hypertonia of the pelvic floor muscles and lower urinary tract function.
- prostate disease may cause changes in the shape and function of the bladder following lower urinary tract disorders (micturition practice, 8: 4 to 48, 2000).
- non-bacterial prostatitis model animals include the following: (1) Model animals produced using lipopolysaccharide (LPS) (Fulmer, BR., Turner, TT .: Effect of inflamat ion on prostatic protein synthesis and Luminal secret ion in vitro .: J. Urol., 162: 248, 1999), (2) Model animals prepared using Dihydrotestosterone + Estradiol (Harris, MT., Feldberg, RS., Lau. , KM. Et al., : Expression of proinf lammatory gene during estrogen-induced inflammation of the rat prostate.
- LPS lipopolysaccharide
- model animals prepared by injecting hydrochloric acid into rat vas deferens (Toshihiro Goto: Basic and clinical studies on prostatitis). 50: 446-455, 1988) and the like.
- the model animals (1) to (4) have the following disadvantages. Specifically, in (1), the prostate tissue damage is limited to the area around the LPS injection, and in (2) and (3), both are produced by hormonal imbalance due to hormone administration. It takes a relatively long time to complete (at least 3 to 4 weeks), and it is not possible to confirm whether the hormone has been administered during the production process.
- An object of the present invention is to provide a model animal (non-human animal) that can be effectively used for the development of a preventive or therapeutic drug for human chronic non-bacterial prostatitis.
- the purpose of the present invention was to mimic the pathology of human chronic nonbacterial prostatitis in terms of histopathological changes in the prostate and the presence or absence of lower urinary tract disorders, and more preferably, further increase in bladder weight.
- the purpose of the present invention is to provide a non-bacterial prostatitis model animal (non-human animal).
- Another object of the present invention is to provide a method for producing the above model animal.
- an object of the present invention is to provide a human non-bacterial
- a method for screening a substance effective for the prevention or treatment of prostatitis and a pharmaceutical composition for preventing or treating human chronic non-bacterial prostatitis, comprising a substance obtained by the method as an active ingredient. That is.
- Another object of the present invention is to provide a method for evaluating the efficacy of a test drug for the prevention of human chronic non-bacterial prostatitis, or the treatment of human chronic non-bacterial prostatitis by using the above model animal.
- the purpose is to provide a method for drug efficacy evaluation.
- the inventors of the present invention have conducted intensive studies day and night. By injecting hydrochloric acid under the prostatic capsule of a non-human animal, histopathological changes of the prostate and lower urinary tract disorders were observed. It has been found that a non-human animal having symptoms mimicking the pathology of human chronic non-bacterial prostatitis can be produced in view of the presence or absence, more preferably, the increase in bladder S content.
- the non-human animal As a pathological model animal of human chronic non-bacterial prostatitis, it is possible to obtain a drug (candidate substance) that is effective in preventing or treating human chronic non-bacterial prostatitis. He further believed that it is possible to evaluate the efficacy of drugs that are effective in preventing or treating human non-bacterial prostatitis.
- the present invention has been completed based on such findings.
- the present invention is a non-bacterial prostatitis model animal listed in the following (1) to (6):
- Non-human animals produced by injecting hydrochloric acid beneath the prostatic capsule, wherein a tissue disorder characteristic of human chronic non-bacterial prostatitis is observed in the prostate tissue or prostate and surrounding tissues;
- a non-bacterial prostatitis model animal which also has lower urinary tract disorders characteristic of chronic non-bacterial prostatitis.
- the lower urinary tract disorder is a urinary storage disorder having at least one symptom selected from the group consisting of pollakiuria, urinary incontinence, and decreased effective bladder capacity (decreased urination volume).
- the non-bacterial prostatitis model animal according to (2) is a non-human animal produced by injecting hydrochloric acid into the prostate under the lateral lobe capsule.
- the present invention provides a method for producing the above non-bacterial prostatitis model animal, which is described in the following (7) to (10):
- Non-bacterial as described in any of (1) to (3) above which comprises injecting hydrochloric acid beneath the prostatic capsule of the non-human animal and raising the non-human animal to cause prostatitis.
- a method for producing a prostatitis model animal comprises injecting hydrochloric acid beneath the prostatic capsule of the non-human animal and raising the non-human animal to cause prostatitis.
- the present invention also provides a method for screening a substance for treating human chronic non-bacterial prostatitis, as described below:
- a test substance is administered to the non-bacterial prostatitis model animal according to any one of the above (1) to (6), and the test substance is treated with a tissue in a prostate gland tissue of the non-bacterial prostatitis model animal.
- a method for screening a substance for treating human chronic non-bacterial prostatitis comprising the step of assaying an improving effect on at least one of disorders or lower urinary tract disorders.
- the lower urinary tract disorder is a urinary storage disorder having at least one symptom selected from the group consisting of pollakiuria, urinary incontinence, and decreased effective bladder capacity (decreased urination volume)
- the present invention also provides a method for screening a substance for preventing human chronic non-bacterial prostatitis, as described below:
- the preliminary non-bacterial prostatitis model animal used in the above (14) is obtained by the method of preparing a non-bacterial prostatitis model animal described in the above (7) to (10). It is a non-human animal without prostatitis that can be obtained by injecting hydrochloric acid below and breeding it within 4 days.
- test substance test drug
- test substance test drug
- a non-bacterial prostatitis animal animal according to any one of (1) to (6) above is administered with a test drug to be evaluated for its efficacy, and the test drug is treated with the non-bacterial prostate gland.
- a method for evaluating the efficacy of a drug for improving human non-bacterial prostatitis comprising a step of testing the effect of improving a tissue disorder or at least one of lower urinary tract disorders in prostate tissue of a model animal of inflammation.
- Lower urinary tract disorder is urinary storage disorder having at least one symptom selected from the group consisting of pollakiuria, urinary incontinence, and decreased effective bladder capacity (decreased urination volume)
- a test drug to be evaluated for efficacy is administered to a non-bacterial prostatitis model animal, and at least one of tissue damage or lower urinary tract disorder in the prostate fibers of the preliminary non-bacterial prostatitis model animal is administered to the test drug.
- a method for evaluating the efficacy of a drug for preventing human non-bacterial prostatitis which comprises testing the effect of inhibiting the occurrence of a drug on one side.
- the lower urinary tract disorder is a urinary storage disorder having at least one symptom selected from the group consisting of pollakiuria, urinary incontinence, and decreased effective bladder capacity (decreased urination volume), (17)
- the preliminary non-bacterial prostatitis model animal used in the above (17) is obtained by the method of preparing a non-bacterial prostatitis model animal described in the above (1) to (6). It is a non-human animal without prostatitis that can be obtained by injecting hydrochloric acid below and breeding it within 4 days.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a substance obtained by using the screening method described in the above (11) or (14):
- the present invention includes the following embodiments:
- non-bacterial prostatitis model animal is a non-prostatitis-free non-human animal obtained by cultivation of hydrochloric acid under the prostatic capsule and cultivation for less than 4 days.
- Example 1 shows that in Example 1 2), rats injected with hydrochloric acid beneath the prostatic capsule (test group: P), rats injected with hydrochloric acid in the vas deferens (comparative group: Y), and rats treated without injection of hydrochloric acid (control group: N)
- the tissue at the site of hydrochloric acid injection was observed from the long-axis plane [the surface of the urethra as the center (the midline of the rat, the vertical direction from the head to the tail), and the tissue was sectioned vertically].
- Fig. 2 shows that in Example 1 2), rats injected with hydrochloric acid under the prostatic capsule (test group: P), rats injected with hydrochloric acid in the vas deferens (comparison group: Y), and rats treated without injection of hydrochloric acid (control group: N)
- the tissue at the site of hydrochloric acid injection was observed from the horizontal axis (the surface of the urethra as the center (the midline of the rat, the vertical direction from head to tail), and the fiber was crossed).
- Fig. 3 is a view showing an image of a long-axis section of the lateral lobe of the prostate and the tissue around the urethra of the prostate tissue collected 8 days after the injection of hydrochloric acid in rats injected with hydrochloric acid under the prostatic capsule. See 2-1)].
- FIG. 4 is a diagram showing images of the prostatic lateral gland cavities and nerve cell groups among prostate tissues collected on day 8 after hydrochloric acid injection in rats injected with hydrochloric acid under the prostatic capsule. )reference ⁇ .
- Fig. 5 shows the experimental results in 3) of Example 1, ie, rats injected with hydrochloric acid under the prostatic capsule (rats injected with 0.1N hydrochloric acid, rats injected with 0.2 hydrochloric acid, and rats injected with 0.4N hydrochloric acid: bred from hydrochloric acid injection for 8 days) It is a figure which shows the urination interval and single urination volume about an eye,) and a control group rat.
- Fig. 6 shows the experimental results in 3) of Example 1, ie, rats injected with hydrochloric acid under the prostatic capsule (rats injected with 0.1N hydrochloric acid, rats injected with 0.2 hydrochloric acid, and rats injected with 0.4N hydrochloric acid: bred from hydrochloric acid injection for 8 days) Eye) and control rats, residual urine volume, and prostate ventral lobe It is a figure which shows a / weight ratio.
- FIG. 7 shows the experimental results in 3) of Example 1, ie, rats injected with hydrochloric acid under the prostatic capsule (rats injected with 0.1N hydrochloric acid, rats injected with 0.2N hydrochloric acid, and rats injected with 0.4N hydrochloric acid: reared from hydrochloric acid injection).
- FIG. 7 is a diagram showing the body weight ratio of the dorsal lobe of the prostate Z and the body weight ratio of the bladder in the rats on the day) and the control group.
- the non-bacterial prostatitis model animal targeted by the present invention is a non-human pathological model animal (non-human animal) that reflects chronic non-bacterial prostatitis in humans.
- the prostate tissue preferably the prostate gland and its surrounding tissue
- the prostate tissue is a human prostate tissue or a prostate tissue affected by chronic non-bacterial prostatitis.
- Non-human animals that also have histopathological features found in the surrounding tissues, as well as lower urinary tract disorders that are unique to human chronic nonbacterial prostatitis.
- the histology consisted of a chronic inflammatory response and proliferation of interstitial fibers, and lymphocytes, plasma cells and macrophages were infiltrated around the lobules. It has been reported that it is often accompanied by hyperplasia of the basal cells of the duct (Surgical Pathology, Bunkodo Co., Ltd., 793-794, 1999).
- the non-bacterial prostatitis model animal to which the present invention is directed specifically has at least the interstitial part of the prostate with features such as inflammatory cell infiltration and increase (proliferation) of connective tissue.
- a preferred model animal of the present invention is a model animal that has been subjected to severe fibroblast proliferation and fibrosis in the stroma of the prostate on day 4 or later. A dagger was observed, and inflammatory cell infiltration (infiltration of macrophages and eosinophils) was observed. The histopathology of the model animal is consistent with that of human chronic nonbacterial prostatitis. In addition, in the model animal, the above-mentioned disorder is observed up to the prostatic tissue around the urethra, and such a fiber disorder persists until day 8 after the model preparation treatment (hydrochloric acid injection).
- the model animal has only a disorder in the prostate tissue and its surrounding tissues, and no disorder in the urethra and bladder tissues. Therefore, the preferred non-bacterial prostatitis model animal of the present invention is the human prostate or the prostate and its surrounding tissues.
- the animal can be a non-human animal that also has a disorder characteristic of chronic non-bacterial prostatitis, but does not have tissue damage to the lower urinary tract tissue, such as the urethra and bladder tissue.
- the pathology of chronic nonbacterial prostatitis in humans includes lower abdominal and perineal pain, discomfort during ejaculation, and lower urinary tract disorders (symptoms related to urination: dysuria such as pollakiuria, and difficulty urinating). Dysuria etc.) have been reported.
- scores of urine, genital and pelvic pain and urination symptoms are used as a questionnaire.
- the most common symptom of chronic nonbacterial prostatitis is urinary symptoms, especially frequent urinary symptoms (urinary dysfunction: short intervals between urination). This is because the bladder becomes overactive due to inflammation of the prostate (uncontrolled bladder contraction, unstable bladder).
- bladder perception is transmitted to the spinal cord via A ⁇ fibers, but during inflammation, C fibers function as injury signaling nerves, and ⁇ ⁇ fibers are added to C fiber perception to become hypersensitive. It has been reported that uncontrolled bladder contraction may occur (urinary dysfunction practice, 8: 97-102, 2000). It has also been reported that such unstable bladder is accompanied by nervous system changes (urination) Disability Practices, 8: 97-102, 2000)
- the non-bacterial prostatitis model animal targeted by the present invention is a non-human animal having at least a lower urinary tract disorder among the above-mentioned pathological conditions (symptoms) characteristically recognized as chronic non-bacterial prostatic prostatitis. Animal.
- symptoms pathological conditions characteristically recognized as chronic non-bacterial prostatic prostatitis.
- animal Of the lower urinary tract disorders, urinary storage disorders having symptoms such as pollakiuria, urinary incontinence, or decreased effective bladder capacity (decreased urination volume) are preferred.
- the preferred model animal of the present invention has a shorter urination interval, a smaller urination volume and a larger residual urine volume than the corresponding normal non-human animal. It is recognized that.
- the pathology (symptoms) of the model animal is consistent with the pathology (symptoms) associated with lower urinary tract disorders in human patients with chronic nonbacterial prostatitis. Therefore, the preferred non-bacterial prostatitis model animal of the present invention includes lower urinary tract disorders characteristic of human chronic non-bacterial prostatitis, at least pollakiuria, and a decrease in effective bladder capacity (a decrease in the volume of a single urination). Or a non-human animal that also has a urinary storage disorder such as residual urine.
- the non-human animal to be measured is weighed and anesthetized with an anesthetic, urethane, in a dose of 1.0 g / kg intraperitoneally. An incision is made in the abdomen to expose the bladder.
- the other side of the catheter is connected to a continuous saline-filled syringe via a saline warming device to inject saline.
- ⁇ Fix the non-human animal to be measured in the prone position, inject saline (37 ° C) at a rate of 5. OmL / hr into the bladder, and measure and record the intravesical pressure over time.
- the amount of urine excreted from the bladder through the ureter can be measured by installing a digital balance directly under the cage containing the non-human animal and trapping the excreted urine cumulatively in the petri dish. Measure and record the change in weight.
- the values of urination interval and micturition volume are calculated by analyzing the results of monitoring the bladder internal pressure waveform and micturition volume 30 minutes to 60 minutes after the start of measurement.
- the non-bacterial prostatitis model animal of the present invention more preferably comprises the above-mentioned delicate (prostate tissue disorder) and pathological features (lower urinary tract) similarly to human chronic non-bacterial prostatitis. Obstacles) and additional elements
- the bladder weight may be increased as compared to the corresponding normal (healthy) non-human animal.
- the increase in bladder weight can be usually evaluated by the weight ratio of bladder to body weight (bladder / body weight) as specifically shown in Examples.
- the non-bacterial prostatitis model animal of the present invention which has the above-described characteristics in terms of the disease and pathological conditions and preferably further increases the bladder weight, is characterized by It can be produced by injecting hydrochloric acid under the prostatic capsule of human animals and breeding them for a certain period of time.
- non-human animals other than humans that can be used for preparing the disease model animal include, for example, rats, nude rats, mice, nude mice, guinea pigs, Humus Yuichi, Egret, dogs, cats, monkeys, etc. Mammals commonly used in conventional experiments. Preferably, it is a rodent such as a rat, a nude rat, a mouse, a nude mouse, a guinea pig, a hamster, a gray heron, etc., and more preferably, a rat, a nude rat, a mouse or a nude mouse in terms of simplicity of operation and breeding. Can be. In addition, when the animal is, for example, a rat, a mouse, or a nude mouse, it is preferable to use a 10 to 12-week-old animal.
- the concentration of hydrochloric acid used in the present invention may be 0.1 to 0.6%. Preferably it is 0.2 to 0.5 °.
- the injection volume varies depending on the type of nonhuman animal to be treated, but it is usually 0.2 to 0.35 ml / kg body weight, preferably 0.25 to 0.3 ml / kg body weight. Can be.
- the method of injecting hydrochloric acid under the prostatic capsule is not particularly limited.
- a simple method for example, a method of injecting and dispensing under the prostatic capsule using a disposable curry syringe loaded with a 27 G intravenous needle can be mentioned.
- Hydrochloric acid is injected under the prostatic capsule of the non-human animal described above.
- Specific examples of the injection site include the lateral lobe of the prostate anatomically approximated to the margin, which is the site where human prostatitis is most likely to occur.
- breeding conditions are not particularly limited, and normal breeding conditions may be employed, or breeding may be performed under antibacterial conditions.
- breeding conditions are temperature 20-26 ° C, relative humidity Degree 30-70%, Lighting 12 hours light / dark cycle, Ventilation rate 10 times / hour or more
- the animals are bred in Z-cage, free feeding of solid feed, from automatic drinking equipment Can be exemplified.
- the breeding period of non-human animals is usually about 3 days to 2 weeks after infusion of hydrochloric acid, and preferably about 4 days to 1 week after infusion of hydrochloric acid.
- the prostate tissue of a non-human animal injected with hydrochloric acid under the prostatic capsule has the same histopathological characteristics as the prostate tissue of a human suffering from chronic nonbacterial prostatitis.
- the non-human animal is a lower urinary tract disorder (particularly frequent urination, decreased urination volume, urinary storage disorder such as residual urine), which is a characteristic condition (symptom) observed in human patients with chronic non-bacterial prostatitis. It has.
- the non-human animal thus produced can be provided as a non-bacterial prostatitis model animal that mimics human chronic non-bacterial prostatitis.
- a more suitable non-bacterial prostatitis model animal that mimics the human chronic non-bacterial prostatitis is a non-human animal after the injection of hydrochloric acid and rearing.
- the non-bacterial prostatitis model animal is used to search for active substances for the treatment of human chronic non-bacterial prostatitis, and to evaluate the therapeutic effects of individual test substances or test drugs on human chronic non-bacterial prostatitis. Can be used effectively.
- the present invention relates to a method for screening a substance effective for treating human chronic non-bacterial prostatitis using a non-bacterial prostatitis model animal that mimics the above-mentioned human chronic non-bacterial prostatitis.
- the method comprises administering a test substance to the non-bacterial prostatitis model animal described above, and subjecting the test substance to the & ⁇ disorder or lower urinary tract disorder in the prostate tissue of the non-bacterial prostatitis model animal. It can be performed by testing the improvement effect on one or both of the above.
- the target non-bacterial prostatitis model animal is not particularly limited as long as it is as described above. It is preferably a rat, a nude rat, a mouse or a nude mouse, more preferably a rat. These are preferably raised for at least 4 days after the injection of hydrochloric acid, preferably for about 4 days to about 1 week, more preferably 8 days after the breeding. Can be
- test substance used here is not particularly limited, and may be any of low-molecular organic or inorganic compounds, high-molecular organic or inorganic compounds, nucleic acids, amino acids, peptides or proteins. These may be purified products or crude products such as extracts of plants, animals or microorganisms.
- the method for producing the test substance is not particularly limited, either, whether it is isolated from a natural product, chemically or biochemically synthesized, or prepared by genetic engineering. May be used.
- the method of administering the test substance to the non-bacterial prostatitis model animal is not particularly limited.
- oral administration or parenteral administration such as subcutaneous, intradermal, intravenous, transdermal, or enteral (rectal) can be appropriately selected. Oral administration is preferred.
- the therapeutic effect of the test substance on human non-bacterial non-bacterial prostatitis is determined by the test substance in treating tissue damage in the prostate tissue (or the prostate and surrounding tissues) or lower urinary tract disorder in non-bacterial prostatitis model animals. It can be evaluated by testing the improvement effect on at least one of them. Specifically, after administering a test substance to a model animal and breeding it for a certain period of time, the prostate tissue (or prostate and its surrounding tissue) is observed and the histopathological characteristics of the model animal are evaluated. In addition, by measuring bladder function (urination volume, frequency of urination, residual urine volume, etc.), tissue damage or lower urinary tract disorder in the prostate tissue or prostate and its surrounding tissues originally possessed by the model animal was determined.
- bladder function urination volume, frequency of urination, residual urine volume, etc.
- the screening method of the present invention can also be performed by evaluating the presence or absence of improvement in either the above-mentioned tissue disorder or lower urinary tract disorder, but it is desirable to evaluate the presence or absence of both improvements.
- the amount of bladder in model animals can be measured, and the effect of suppressing bladder weight gain can be used as one of the indicators of improvement.
- the pathological tissue is evaluated by staining the target tissue with hematoxylin and eosin (HE) to prepare a ⁇ -specimen slide and observing it at an observation magnification of 20 to 100 times using an optical microscope. be able to.
- the test model Observe the animal's prostate tissue (prostate and its surrounding fibers) with a light microscope, and observe the histopathological changes in the corresponding organs of a normal non-human animal (prostate tissue (or prostate and its surrounding tissue)).
- the evaluation criteria for the pathological grade [Dare (disability): 1: no change [no change compared to normal non-human animal tissue (normal tissue)], 2: slight [compared to normal tissue] Changes are not noticeable for the first time], 3: Mild [1/4 of tissue damage], 4: Moderate damage to about 1/2, 5: Severe [Clear tissue damage of 1/2 or more])
- the index can be used to evaluate the histopathology of the test animal model.
- the presence or absence of an improvement effect on tissue damage can be determined by the change in the above grade (disability degree) of the test animal model (decrease in grade: improved effect, increase in grade: no improved effect).
- the prostate disorder and / or lower urinary tract disorder of the non-bacterial prostatitis model animal before administration of the test substance is improved, and the prostate tissue (histological image) and bladder function of the corresponding normal non-human animal are improved.
- a test substance having an effect of approximating the above, and more preferably a test substance having an effect of further suppressing an increase in bladder weight can be selected as a substance effective for treating human chronic non-bacterial prostatitis. .
- the selection of such a therapeutically active substance is carried out in a control non-bacterial prostatitis model animal (comparative animal) to which no test substance is administered, similarly after breeding for a certain period of time, in the prostate gland tissue (or in the prostate and / or prostate). Measure the tissue damage and Z or bladder function of the surrounding tissues) and, if necessary, the bladder weight, and compare the results with the above results obtained for test animals administered the test substance and bred for a certain period of time. It can also be done by doing things.
- an effect of improving the harmful effects of tissue P such as prostate tissue and Z or Z or bladder function of the test animal, or the prostate tissue and Z or bladder function of the test animal, and bladder weight (weight of bladder Z weight)
- tissue P such as prostate tissue and Z or Z or bladder function of the test animal, or the prostate tissue and Z or bladder function of the test animal, and bladder weight (weight of bladder Z weight)
- the test substance having an effect of bringing the ratio of the test substance closer to that of a normal non-human animal can be selected as the therapeutically active substance.
- the substance thus selected can be usefully used as an active ingredient of a therapeutic agent for human chronic non-bacterial prostatitis.
- the therapeutically active substance for human chronic non-bacterial prostatitis selected by the above-described screening method of the present invention can be further subjected to other pharmacological tests and safety tests as necessary, Clinical trial for patients with chronic nonbacterial prostatitis in humans By conducting experiments, it is possible to select therapeutically effective substances that are more effective and more practical.
- the therapeutically active substance thus selected can be industrially produced by chemical synthesis, biochemical synthesis (fermentation) or genetic manipulation based on the results of its structural analysis.
- the present invention further relates to a method for screening a substance effective for preventing human chronic non-bacterial prostatitis.
- the method is carried out by using a so-called preliminary non-bacterial prostatitis model animal that has not developed prostatitis, which is obtained in the process of preparing the non-bacterial prostatitis model animal of the present invention as described above. Can be.
- the non-bacterial prostatitis model animal is prepared under the prostatic capsule of a non-human animal, preferably under the prostatic lateral lobe coating, as in the preparation of the non-bacterial prostatitis model animal. It can be produced by injecting hydrochloric acid in the following manner.
- a non-human animal that has not developed prostatitis, immediately after or at the beginning of the injection of hydrochloric acid, can be defined as a spare / non-bacterial prostatitis model animal.
- prostatitis specifically refers to the state in which the specific prostate tissue or the prostate and its surrounding tissues, which are specific to the above-mentioned non-bacterial prostatitis model animal, have substantially no tissue damage, and It means that there is virtually no urinary tract disorder.
- non-human animals that have been bred for less than 4 days immediately after or after the injection of hydrochloric acid can be used.
- a test substance is administered to the preliminary 'non-bacterial prostatitis model animal, and the test substance is treated with a tissue in the prostate tissue (or prostate and its surrounding tissue) of the preliminary non-bacterial prostatitis model animal. This can be done by testing the inhibitory effect on at least one of the occurrence of disorders or lower urinary tract disorders.
- test substance used here and its administration method are described in (2) above. And methods can be mentioned as well.
- the prophylactic effect of the test substance on human chronic non-bacterial prostatitis includes the following: Preliminary effects of the test substance: The effect of suppressing tissue damage in prostate tissue (or prostate and surrounding tissues) in non-bacterial prostatitis model animals; It can be evaluated from the effect of suppressing the occurrence of lower urinary tract disorders.
- the prostate tissue (or prostate and its surroundings) Of the non-bacterial prostatitis model animal by monitoring histopathology and evaluating histopathological characteristics and measuring bladder function (single urination volume, frequency of urination, residual urine volume, etc.) This can be done by assessing whether a tissue disorder or lower urinary tract disorder has occurred.
- the screening method of the present invention can also be performed by evaluating the presence or absence of any of the above-mentioned tissue disorders or lower urinary tract disorders (the effect of suppressing the occurrence), but it is desirable to evaluate both.
- the method described above in (2) can be similarly used.
- the presence or absence of a preventive effect on tissue damage can be determined by the change in the above grade (chapter P, harmfulness) of the test model animals (no increase in grade: preventive effect, increase in grade: no preventive effect).
- test model animals preliminary and non-bacterial prostatitis model animals
- tissue damage of the prostate tissue or prostate and surrounding tissues
- the Z or lower urinary tract disorder of the non-bacterial prostatitis model animals A test substance that suppresses development and maintains the prostate tissue (histological image) and bladder function of a normal non-human animal corresponding to a model animal, and preferably further suppresses an increase in bladder weight
- the test substance having the effect of causing the disease can be selected as an effective substance for preventing human chronic nonbacterial prostatitis.
- the selection of such a prophylactically active substance should be determined in the same way as for the control spare / non-bacterial prostatitis model animals (comparative animals) to which the test substance is not administered.
- Peripheral tissue) tissue disorders and Z or bladder function Further, the measurement can be performed by measuring the bladder weight as needed, and comparing the results with the above-mentioned results obtained from a test animal administered with the test substance and raised for a certain period of time.
- the prostate tissue and Z or bladder function of the subject animal and, if necessary, the bladder weight (weight ratio of S paravesical / body weight) were changed to the state of the prostate tissue and / or bladder function of a normal non-human animal.
- the test can be carried out by selecting a test substance having an effect of maintaining the bladder weight (bladder / body weight ratio) or a state close to it as necessary.
- the substance thus selected can be usefully used as an active ingredient of a prophylactic agent for human chronic non-bacterial prostatitis.
- the prophylactically effective substance for human chronic non-bacterial prostatic inflammation selected by the above-described screening method of the present invention can be further subjected to other pharmacological tests and safety tests as necessary, and Furthermore, by conducting clinical tests on humans, it can be selected as a more effective and highly practical preventive active substance.
- the prophylactically active substance thus selected can be industrially produced by chemical synthesis, biochemical synthesis (fermentation) or genetic work based on the results of its structural analysis.
- Substances effective for the treatment or prevention of human chronic non-bacterial prostatitis obtained by the above-mentioned screening can be used as such or as a pharmaceutically acceptable carrier (excipient, bulking agent, binder, lubricant) known per se. Or the like) or a conventional additive or the like to prepare a pharmaceutical composition.
- a pharmaceutically acceptable carrier excipient, bulking agent, binder, lubricant known per se. Or the like
- a conventional additive or the like to prepare a pharmaceutical composition.
- the present invention provides a pharmaceutical composition for treating or preventing such human chronic non-bacterial prostatitis.
- these active ingredients are not limited to those selected and directly obtained by the above method, but may be chemically, biochemically or genetically engineered in accordance with a conventional method based on information on the substances selected above. It may be manufactured by a technique.
- the pharmaceutical composition is orally or parenterally administered depending on the form to be prepared (tablets, pills, capsules, powders, granules, syrups; injections, drops, external preparations, suppositories) and the like.
- the dosage varies depending on the type of active ingredient, administration route, administration subject or symptoms, etc., and cannot be specified unconditionally.However, 0.001 to 5 g per day is divided into 1 to several times a day. Can be administered.
- the present invention provides a method for evaluating the efficacy of a test drug for ameliorating and treating human chronic nonbacterial prostatitis using a nonbacterial prostatitis model animal that mimics the above human chronic nonbacterial prostatitis. About.
- the method comprises administering a test drug to the non-bacterial prostatitis model animal described above, and subjecting the test drug to the prostate fibers (or prostate and surrounding tissues) of the non-bacterial prostatitis model animal. It can be implemented by evaluating at least one of the improvement effect on the tissue disorder (therapeutic effect) or the improvement effect on the lower urinary tract disorder (therapeutic effect).
- the non-human animal described above in (3) can be used in the same manner.
- the drug used as the test drug is not limited to those in the form of a drug, regardless of the degree of the effect, as long as the drug has an improving effect (therapeutic effect) on human chronic non-bacterial prostatic inflammation. Not done. Therefore, any of low molecular organic or inorganic compounds, high molecular organic or inorganic compounds, nucleic acids, amino acids, peptides or proteins can be targeted. These may be purified products or crude products such as extracts of plants, animals or microorganisms. Regardless of the type of acquisition, they may be isolated from natural products, chemically or chemically synthesized, or prepared by genetic engineering. There may be.
- the method of administering the test drug to the non-bacterial prostatitis model animal is not particularly limited.
- oral administration or parenteral administration such as subcutaneous, intradermal, intravenous, transdermal, or enteral (rectal) can be appropriately selected. Oral administration is preferred.
- Evaluation of the efficacy of the test drug on amelioration of human chronic non-bacterial prostatitis was performed using the prostate tissue (or prostate and its prostate) of a non-bacterial prostatitis model animal. It can be evaluated by examining at least one of the improvement effect on disorders in peripheral tissues) or the improvement effect on lower urinary tract disorders. Specifically, after the test drug is administered to a non-bacterial prostatitis model animal, the animal is bred for a certain period of time, and then the prostate tissue, the prostate and its surrounding tissue) are observed and the histopathology of the model animal is examined.
- Evaluation should be performed by assessing the characteristics and / or bladder function (urinary output, urination frequency, residual urine volume, etc.) to evaluate the degree of improvement of the model animal against tissue disorders and lower urinary tract disorders.
- characteristics and / or bladder function urinary output, urination frequency, residual urine volume, etc.
- the bladder weight of a model animal can be measured, and the degree of suppression of bladder weight increase can be used as one index of drug efficacy evaluation.
- the degree of improvement in tissue damage is determined, for example, by the evaluation criteria for the pathological grade described above in (3) above (grade (degree of damage): 1: no change [change in comparison with the tissue of normal non-human animal (normal tissue)] No], 2: Minor [Change is only noticeable compared to normal tissue], 3: Mild [Tissue damage is about 1/4], 4: Moderate [Tissue damage is about 1/2], 5 : Severe [obviously the fiber disorder is 1/2 or more]].
- grade (degree of damage) 1: no change [change in comparison with the tissue of normal non-human animal (normal tissue)] No]
- 2 Minor [Change is only noticeable compared to normal tissue]
- 3 Mild [Tissue damage is about 1/4]
- 4 Moderate [Tissue damage is about 1/2]
- 5 Severe [obviously the fiber disorder is 1/2 or more]].
- Evaluation of the efficacy of the test drug on the improvement of human chronic non-bacterial prostatitis was carried out using one or more drugs whose therapeutic effect and the degree of human
- Drugs known to have a therapeutic effect on human chronic nonbacterial prostatitis include new quinolone drugs (eg, sparf loxacin (Spara), levof laxacin (Cravit), etc.), tetracycline antibacterial drugs (eg, minocycline, doxycycline, etc.) And non-steroidal anti-inflammatory drugs (eg, ibuprofen, indomethacin, etc.), botanicals (eg, sernilton, ebiprostat, paraprost, etc.), and Kampo medicines (eg, Keishibukuryogan, Shimotsuto).
- new quinolone drugs eg, sparf loxacin (Spara), levof laxacin (Cravit), etc.
- tetracycline antibacterial drugs eg, minocycline, doxycycline, etc.
- non-steroidal anti-inflammatory drugs eg, ibuprofen, indomethacin, etc.
- the present invention relates to a method for evaluating the efficacy of a drug for preventing human chronic non-bacterial prostatitis.
- the method comprises the steps of preparing a non-prostatitis-free so-called preliminary non-bacterial prostatitis model animal obtained in the process of preparing the non-bacterial prostatitis model animal of the present invention described in (1) and (4) above. It can be implemented by using
- a test drug is administered to the preliminary non-bacterial prostatitis model animal, and the test drug is administered to the prostate tissue (or prostate and surrounding tissue) of the preliminary non-bacterial prostatitis model animal. It can be carried out by evaluating at least one of the effect of inhibiting the occurrence of a disorder (preventive effect) or the effect of inhibiting the occurrence of a lower urinary tract disorder (preventive effect).
- test drug used here is not limited to one that takes the form of a drug, regardless of the degree of effect, as long as it has a preventive effect (occurrence suppressing effect) against human chronic non-bacterial prostatitis. Therefore, any of low-molecular organic or inorganic compounds, high-molecular organic or inorganic compounds, nucleic acids, amino acids, peptides, and proteins can be targeted. These may be purified products, or may be crude products such as extracts of plants, animals or microorganisms. Regardless of whether they are obtained or not, they may be isolated from natural products, chemically or biochemically synthesized, or genetically engineered. Good. As the administration method, the method described above in (5) can be similarly mentioned.
- the evaluation of the efficacy of a test drug for the prevention of human chronic non-bacterial prostatitis is based on tissue damage in the prostate tissue (or prostate and its surrounding tissue) of a preliminary non-bacterial prostatitis model animal. It can be evaluated by examining the effect of suppressing the occurrence and the effect of suppressing the occurrence of Z or lower urinary tract disorders.
- the bladder weight of a model animal can be measured, and the degree of suppression of the increase in bladder weight can be used as one of the indices for evaluating efficacy.
- the degree of suppression of the occurrence of tissue damage is determined, for example, by the evaluation criteria for the pathological grade described above in (3) above (grade (degree of damage): 1: no change [compared to the tissue of normal non-human animal (normal tissue)]. No change), 2: Minor [A change is only noticeable compared to normal tissue], 3: Mild [Tissue damage is about 1/4], 4: Moderate [Tissue damage is about 1/2] , 5: Severity [obviously tissue damage is more than 1/2]].
- Evaluation of the efficacy of a test drug for the prevention of human chronic non-bacterial prostatitis was carried out using one or more drugs, for which the preventive effect and the degree of human chronic non-bacterial prostatitis are known, as comparative drugs. More easily implemented by comparing the drug's reserve with the preventive effect on non-bacterial prostatitis model animals (the preventive effect on textile disorders and / or lower urinary tract disorders, and, if necessary, the effect of suppressing bladder weight increase) Can be done.
- the drugs that have a preventive effect on human chronic non-bacterial prostatitis include plant preparations (eg, cell elton, ebipros, parablost, etc.) and Chinese herbal medicines (eg, keishibukuryogan, shimotsuto) Etc.) can be exemplified.
- plant preparations eg, cell elton, ebipros, parablost, etc.
- Chinese herbal medicines eg, keishibukuryogan, shimotsuto
- test group Eighteen 12-week-old Wistar male rats were divided into three groups (test group, comparative group, and negative control group: six in each group).
- test group the right inguinal region was incised under ether anesthesia, and sterilized 0.4N hydrochloric acid saline (0.4N concentration) was placed under the right lobe of the exposed prostate. Hydrochloric acid prepared with physiological saline so that same as below. ) was injected in 100 l.
- control group the right groin was incised under ether anesthesia, and 100 L of 0.4N hydrochloric acid saline was injected into the exposed right vas deferens in the seminal vesicle direction.
- an aqueous solution containing kanamycin was sprayed into the incision, and an aqueous solution containing sodium cefazolin was injected into the thigh muscle at a rate of 7 mg / kg body weight.
- Three cages are housed in R-IS type (260 x 380 x 180 mm: Claire Japan) stainless steel rat bracket cages.
- the prostate, bladder and urethra were collected from the rats of each group (test group, comparative group, and control group) prepared in the above 1), and each tissue specimen was prepared to evaluate the change in tissue. Specifically, for each of the rats in the test group and the comparative group, 6 hours (2 rats per group), 4 days (2 rats per group), and 8 days after injection of hydrochloric acid (2 rats per group) at each time point The animals were euthanized by exsanguination under ether anesthesia, and the prostate, bladder, and urethral tissues were collected as one lump, and each tissue was fixed with 4% paraformaldehyde. Control rats were treated in the same manner.
- 1% of the immobilized thread was added to OCT compound (Tissue-Tek 0. CT compound [Sakura Finetechnical Co., Ltd.,]; 10.24 w / w% polyvinyl alcohol, 4.26 w / w% polyglycol ⁇ " , 85.50 w / w% inactive ingredient) to prepare a frozen block, which is then cut at 5-6 rn thickness in a cryostat, and a slide specimen of a tissue section is prepared. Then, the slide specimen was stained with hematoxylin-eosin (HE), and the state of the tissue was observed under a microscope.
- OCT compound Tissue-Tek 0. CT compound [Sakura Finetechnical Co., Ltd.,]; 10.24 w / w% polyvinyl alcohol, 4.26 w / w% polyglycol ⁇ " , 85.50 w / w% inactive ingredient
- Rats injected with 0.4 N hydrochloric acid saline under the right lobe capsule (test group: rats injected with hydrochloric acid under the prostatic capsule) at 6 hours, 4 days, and 8 days after hydrochloric acid injection Observed and evaluated findings of prostate tissue are shown in Fig. 1 (findings on the long axis of the prostate) and Fig. 2 (findings on the horizontal axis of the prostate), together with the corresponding tissues of the control group (rats not treated with hydrochloric acid).
- sample number N indicates a tissue sample of a control group (rats not injected with hydrochloric acid)
- P indicates a tissue sample of a test group (rats injected with hydrochloric acid under the prostatic capsule).
- the prostate gland tissue (sample number: P) of rats injected with 0.4 N hydrochloric acid in the prostate lateral lobe was slightly in the glandular cavity of the dorsal lobe of the prostate at 6 hours after injection. From (+) to moderate (++) to severe (HI), glandular epithelial cell shedding, epithelial detachment, degenerative necrosis, and the presence of erythrocytes were observed [Fig. L (a), Fig. 2 ( a)]. In addition, mild (+) to moderate (++) localized hemorrhage and neuronal tiger plaque fusion were observed in the interstitium of the dorsal lobe of the prostate [Fig. 2 (a)]. On the fourth day after the injection of hydrochloric acid, the gland cavity and its surroundings Hemorrhage and atrophy of the glandular cavity, and moderate in the interstitium of the dorsal lobe of the prostate
- Prostate tissue and vas deferens were observed at 6 hours, 4 days, and 8 days after injection in rats (comparative group) in which 0.4 1 ⁇ hydrochloric acid saline was injected 100/1 into the vas deferens
- the findings of glandular tissues and vas deferens tissues are shown in Fig. 1 (findings on the long axis) and Fig. 2 (findings on the horizontal axis).
- the sample number Y indicates a tissue sample of the comparative group (rats injected with hydrochloric acid in the vas deferens).
- each group was sterilized under the right lobe of the prostate of 12-week-old Wistar male rats (group 3) under 0.1, 0.2, or 0.4N. Hydrochloric saline was injected in 100 l portions, and reared for 8 days under the same conditions as above.
- the rat produced in this manner was subjected to voiding interval, tidal volume, residual urine volume, and the weight ratio of prostate gland, prostate dorsal lobe and bladder to body weight (prostate ventral lobe Z body weight, prostate dorsal lobe) Z body weight and bladder Z body weight) were examined, and bladder function (the presence or absence of lower urinary tract disorders) was evaluated (test group).
- the rat was fixed in a supine position under urethane anesthesia (lg / kg ip), the lower abdomen was shaved, and after laparotomy, intraperitoneal More exposed bladder. A small incision was made at the top of the bladder, and about 6 thighs of polyethylene catheter (PE-50: Nippon Becton 'Dickinson KK) were inserted, and the incision was sutured and fixed.
- PE-50 Nippon Becton 'Dickinson KK
- the other end of the force catheter inserted and fixed in the paraperitoneum is bisected via a three-way stopcock, and one of them is used to measure the bladder internal pressure using a transducer (a disposable blood pressure monitoring life kit DX-360, Nihon Kohden).
- a transducer a disposable blood pressure monitoring life kit DX-360, Nihon Kohden.
- a pressure amplifier Nippon Electric Sanei, 2238
- inject saline into the bladder and to inject a saline warmer (BLOOD WATER T-90, T0RAY CO., LTD.)
- a continuous injector Tel-Fu Syringe Pump STC_521, Terumo Corporation.
- the rat was fixed in a prone position in a Pori Leman cage (Yamashita Giken Co., Ltd.), and a saline solution maintained at about 37 ° C. was continuously infused into the bladder at a constant rate (5 mL / hr).
- the urination interval can be measured specifically as follows. In other words, when saline is infused into the bladder at a constant rate, the internal pressure gradually increases, and when a certain threshold is exceeded, the internal pressure rises at an acute angle, reaches a peak, and urinates, and after urination, the internal pressure drops rapidly (Urinary reflex). Continuous infusion repeats these voiding reflexes. The time between the peak of the bladder pressure (maximum bladder contraction pressure) and the peak (maximum bladder contraction pressure) is evaluated as the urination interval. The urination volume is determined by reading the value of urine weight that changes when urinating the electronic balance placed directly below the rat (European Neurosurgical Research, Nippon Medical Center, p. 158-165, 2000). At the end of urination, the amount of residual urine is evaluated from the weight of the urine stored in the bladder by suction using a syringe.
- the abdominal lobe of the prostate, the dorsal lobe of the prostate, and the bladder were taken out and their weight was measured.
- a control group (pseudo-injection) was injected under the right lobe of the prostate of 12-week-old Wistar male rats under saline in the same manner as saline 1001 instead of saline.
- bladder function Presence or absence of lower urinary tract disorders
- the method of the present invention in which hydrochloric acid is injected into the prostate lateral lobe has an effect on bladder function.
- the impact is considered to be very large.
- the difference in hydrochloric acid concentration to be injected suggests that by adjusting the concentration of hydrochloric acid, it is possible to produce non-bacterial prostatitis model animals for different purposes. For example, rats injected with 0.1 N hydrochloric acid had no residual urine, judging from the results equivalent to those of the control group, and showed the lowest urination interval and single urination volume.
- Rats injected with 0.2N hydrochloric acid had a slightly higher residual urine volume, and although not as large as rats injected with 0.1N hydrochloric acid, the voiding interval and single voiding volume were lower than those in the control group. Based on the above, it is considered to be a non-bacterial prostatitis model with lower urinary tract obstruction. Furthermore, rats injected with 0.4N hydrochloric acid had the highest residual urine volume, and urination volume was lower than rats injected with 0.2N hydrochloric acid. It is possible that this is a non-bacterial prostatitis model.
- the bladder of the test group (model animal of the present invention) showed an increase in the weight depending on the concentration of the injected hydrochloric acid.
- the hydrochloric acid concentration and weight change increase in prostate weight (prostatic hypertrophy) or prostate atrophy). From these facts, the difference in the concentration of hydrochloric acid to be injected changes the constitution of the prostate tissue or the degree of influence on the nervous system in the prostate, and the degree of the lower urinary tract obstruction (residual volume Change) may be reflected in the bladder weight.
- the non-bacterial prostatitis model animal (non-human animal) provided by the present invention may be a human animal in view of the pathological changes of the prostate and the presence or absence of obstruction of the urinary tract, and more preferably, the increase of bladder weight This is a disease model animal that mimics the condition of chronic nonbacterial prostatitis. Therefore, according to the model animal, a substance effective for prevention or treatment of human chronic non-bacterial prostatitis can be searched and selected and effectively used for IJ. Further, according to the model animal, it can be effectively used for evaluating the efficacy of a drug for preventing or treating human chronic non-bacterial prostatitis. That is, the non-bacterial prostatitis model animal (non-human animal) provided by the present invention is useful for the development of a drug for preventing or treating human chronic non-bacterial prostatitis. It can be used for effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/533,013 US20060107336A1 (en) | 2002-10-29 | 2003-10-28 | Nonbacterial prostatitis model animal |
EP03758961A EP1559317A4 (en) | 2002-10-29 | 2003-10-28 | ANIMAL MODEL WITH NON-BACTERIAL PROSTATITIS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-313960 | 2002-10-29 | ||
JP2002313960A JP3921664B2 (ja) | 2002-10-29 | 2002-10-29 | 非細菌性前立腺炎モデル動物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004039148A1 true WO2004039148A1 (ja) | 2004-05-13 |
Family
ID=32211596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013743 WO2004039148A1 (ja) | 2002-10-29 | 2003-10-28 | 非細菌性前立腺炎モデル動物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060107336A1 (ja) |
EP (1) | EP1559317A4 (ja) |
JP (1) | JP3921664B2 (ja) |
WO (1) | WO2004039148A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008043243A1 (fr) * | 2006-09-08 | 2008-04-17 | Zhiren Liu | Utilisation d'acide chlorhydrique dans la fabrication de médicament destiné au traitement de maladie entraînée par... |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014079188A (ja) * | 2012-10-16 | 2014-05-08 | Kimio Sugaya | 無菌性慢性前立腺炎非ヒトモデル動物、頻尿非ヒトモデル動物およびこれらを用いた被験物質の評価方法 |
WO2016178393A1 (ja) * | 2015-05-01 | 2016-11-10 | Cyberdyne株式会社 | モデル動物の機能改善評価装置および神経細胞培養装置 |
CN113425735A (zh) * | 2021-07-05 | 2021-09-24 | 大连医科大学 | 曲札茋苷在治疗小鼠慢性非菌性前列腺炎症中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1055426A1 (en) * | 1998-11-05 | 2000-11-29 | Taiho Pharmaceutical Company, Limited | Dysuria remedies |
-
2002
- 2002-10-29 JP JP2002313960A patent/JP3921664B2/ja not_active Expired - Fee Related
-
2003
- 2003-10-28 EP EP03758961A patent/EP1559317A4/en not_active Withdrawn
- 2003-10-28 US US10/533,013 patent/US20060107336A1/en not_active Abandoned
- 2003-10-28 WO PCT/JP2003/013743 patent/WO2004039148A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1055426A1 (en) * | 1998-11-05 | 2000-11-29 | Taiho Pharmaceutical Company, Limited | Dysuria remedies |
Non-Patent Citations (4)
Title |
---|
GOTO TOSHIHIRO: "Zenritsusen'en no Kisoteki Rinshoteki Kento", THE NISHINIHON JOURNAL OF UROLOGY, vol. 50, 1988, pages 446 - 455, XP002979147 * |
KEETCH D. W. ET AL.: "Development of a mouse model for nonbacterial prostatitis", J. UROL., vol. 152, no. 1, July 1994 (1994-07-01), pages 247 - 250, XP002979149 * |
LANG M. D. ET AL.: "Rat model of experimentally induced abacterial prostatitis", PROSTATE, vol. 45, no. 3, 1 November 2000 (2000-11-01), pages 201 - 206, XP002979150 * |
ROBINETTE C. L.: "Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate", PROSTATE, vol. 12, no. 3, 1988, pages 271 - 286, XP002979148 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008043243A1 (fr) * | 2006-09-08 | 2008-04-17 | Zhiren Liu | Utilisation d'acide chlorhydrique dans la fabrication de médicament destiné au traitement de maladie entraînée par... |
Also Published As
Publication number | Publication date |
---|---|
EP1559317A4 (en) | 2007-10-24 |
US20060107336A1 (en) | 2006-05-18 |
EP1559317A1 (en) | 2005-08-03 |
JP3921664B2 (ja) | 2007-05-30 |
JP2004147521A (ja) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3951270B2 (ja) | 前立腺間質肥大モデル動物 | |
Zhang et al. | STING mediates neuroinflammatory response by activating NLRP3‐related pyroptosis in severe traumatic brain injury | |
KR20200103680A (ko) | 치매를 포함하는 신경 장애에 대한 치료 조성물 및 방법 | |
US20130202534A1 (en) | Pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency | |
KR100375003B1 (ko) | 배뇨장애 치료제 | |
WO2004039148A1 (ja) | 非細菌性前立腺炎モデル動物 | |
EP2223699B1 (en) | Radical therapeutic agent for keloid and hypertrophic scar | |
EP3957313A1 (en) | Use of stem cell exosomes for treating overactive bladder | |
WO2022241985A1 (zh) | H1组胺受体拮抗剂在制备治疗神经胶质瘤的药物中的应用 | |
CN112402428B (zh) | 瑞马唑仑在制备治疗阿片类药物诱发的术后痛觉过敏的药物中的应用 | |
CN113521046A (zh) | 丁酸钠在预防或制备治疗偏头痛药物中的应用 | |
CN115671287B (zh) | Feingold综合征Ι型治疗药物及其应用 | |
US20060179492A1 (en) | Method of inhibiting neural transmission mediated by serotonin-2a and enhancing sensorimotor gating | |
Gunn‐Moore | Feline lower urinary tract disease: an update | |
Lopez | Study of the Effects of Contusion Spinal Cord Injury and Optogenetic Stimulation on Lower Urinary Tract Function | |
RU2629717C2 (ru) | Способ малоинвазивного лечения недержания мочи | |
Yang et al. | Hydrogen Attenuates Cognitive Impairment in Rat Models of Vascular Dementia by Inhibiting Oxidative Stress and NLRP3 Inflammasome Activation | |
WO2012121529A2 (ko) | Ninjurin 활성 억제제를 포함하는 신경세포 또는 내피세포 재생용 조성물 | |
US20060107338A1 (en) | Hepatic cirrhosis model animal and method of constructing the same | |
AU2022374290A1 (en) | Medicine for preventing or treating enteritis and intestinal cancer | |
Singh | Therapeutic Ultrasound-Induced Insulin Release | |
CN117771372A (zh) | Klk8或其编码基因作为靶标在制备抑郁症预防、治疗或诊断产品中的用途 | |
AU2010221435B2 (en) | Clostridial toxin to improve ejaculate | |
CN115089714A (zh) | 肝脏环氧化物水解酶作为治疗脑损伤相关疾病神经保护药物的筛选靶点的应用 | |
Deba et al. | FUNCTIONAL EVIDENCE OF β3-ADRENOCEPTORS (β3-AR) IN FEMALE MOUSE ISOLATED URINARY BLADDER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006107336 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10533013 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003758961 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003758961 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10533013 Country of ref document: US |